ArQule shares plunge on amended PhIII plans; Syndax signs China deal on entinostat; Roche partners with Wilex on ADCs;

@FierceBiotech: AstraZeneca rolls the dice (again) on a failed cancer drug. More | Follow @FierceBiotech

@JohnCFierce: Be sure to check out our new weekly report: FierceDiagnostics | Follow @JohnCFierce

@RyanMFierce: Rare diabetes drug development startup Elcelyx Tx spins off nutraceutical assets into NaZura BioHealth. Release | Follow @RyanMFierce

@EmilyMFierce: Altered gene in mice extends lifespan by 20%. Story | Follow @EmilyMFierce

> Shares of ArQule ($ARQL) plunged after the biotech and its partner Daiichi Sankyo said they would amend plans for a Phase III trial of tivantinib, using a lower dose after cases of neutropenia raised safety concerns about the therapy. The drug has already generated poor data in recent months. Story

> Waltham, MA-based Syndax has struck a licensing deal with China's Eddingpharm covering the commercialization of entinostat in China and other Asian countries. Release

> Germany's Wilex AG says its subsidiary Heidelberg Pharma signed a license agreement with Roche ($RHHBY) covering the development of a class of antibody drug conjugates. Release

> Watertown, MA-based Enanta ($ENTA) has won a $9.2 million funding award from the National Institute of Allergy and Infectious Diseases covering a new class of bridged bicyclic antibiotics known as Bicyclolides. Release

> Elcelyx Therapeutics is spinning out NaZura BioHealth to focus on the development of Gut Sensory Modulators. Release

Medical Device News

@FierceMedDev: 'Brain window' implant could enable targeted treatments. Item | Follow @FierceMedDev

@MarkHFierce: bioMerieux's $450M BioFire Dx buy gives it an even greater foothold in infectious disease diagnostics. Story | Follow @MarkHFierce

> Johns Hopkins: Robotic surgery complications grossly underreported. More

> Bard embraces urology home care with $262M Rochester Medical bid. Article

> Biomet metal hip lawsuit to proceed. News

Pharma News

@FiercePharma: India approves $1.6bn acquisition of Agila Specialties by Mylan. More | Follow @FiercePharma

@EricPFierce: ICYMI: Indian regulators find no serious problems at Wockhardt plant banned by FDA. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: How a peptide and a protein can help predict heart attack--and ease overcrowding in the emergency room. More from FierceBiomarkers Follow @CarlyHFierce

> Onyx CEO Tony Coles will score $58M on Amgen deal. Story

> China talks about massive fines against GSK. More

> Eli Lilly's Alimta gains may cause Princeton pain. Article

Drug Delivery News

@MichaelGFierce: Self-powered nanomeds deliver bone-strengthening drugs. Article | Follow @MichaelGFierce

> Oramed submits pre-IND for oral exenatide Type 2 diabetes pill. More

> Meda buys Acton for $135M+, snags asthma inhaler. Item

> Google invests in oral drug delivery for insulin, other biologics. Story

> Nanosized DNA cages could deliver drugs with triggered release. Report

> Novan collects $7.8 million from gov to develop nitric oxide burn med. News

Diagnostics News

> BioFire Diagnostics keeps identity in $450M bioMérieux deal. Story

> Indian Dx giant emerges. Article

> ITC, Accumetrics merge with eye on global cardiovascular Dx. News

> Study: PET/MRI combo adds heft in cancer Dx. Report

> Cepheid wins key 'moderate complexity' designation for combo TB test. More

> Siemens co-develops Alzheimer's blood test. Item

Biomarkers News

> Biomarker sorely needed for diagnosing chronic migraines. Story

> Heart attack biomarker could ease ER crowding. News

> Researchers zero in on biomarker for early diagnosis of ovarian cancer. Report

> Blood test flags organ transplant injury. Item

> Study: Protein may predict mesothelioma survival. More

> Biomarker test boosts prospects for Parkinson's prediction. Article

And Finally... Shortly after completing its IPO, KaloBios ($KBIO) is setting up a $100 million ATM. Story

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.